Vascular Protection to Increase the Safety of Tissue Plasminogen Activator for Stroke

Author(s): Tauheed Ishrat, Sahar Soliman, Weihua Guan, Mihaela Saler, Susan C. Fagan

Journal Name: Current Pharmaceutical Design

Volume 18 , Issue 25 , 2012

Become EABM
Become Reviewer
Call for Editor


Thrombolytic therapy with tissue plasminogen activator (tPA) remains the most effective treatment for acute ischemic stroke, but can cause vascular damage leading to edema formation and hemorrhagic transformation (HT). In this review, we discuss how tPA contributes to the pathogenesis of vascular damage and highlight evidence to support combination therapy of tPA with pharmacological agents that are vascular protective. There is an unmet need to develop therapeutic interventions which target the underlying mechanisms of vascular damage after acute ischemic stroke in order to prevent HT and improve the safety and impact of tPA.

Keywords: Ischemic stroke, vascular protection, tissue plasminogen activator (tPA), matrix metalloproteinases (MMPs), hemorrhagic transformation (HT), thrombolysis, blood–brain barrier, edema formation, vascular damage, clinical trials.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Published on: 17 July, 2012
Page: [3677 - 3684]
Pages: 8
DOI: 10.2174/138161212802002779
Price: $65

Article Metrics

PDF: 10